Following a strong turnout and engaging discussion in January, Life Science Washington is pleased to welcome Eli Lilly back to share its corporate venture and business development strategy with the Washington life sciences community.
Join us for Part II of our Strategic Investor Spotlight featuring Eli Lilly, a global medicine company with nearly 150 years of experience turning science into healing to improve lives around the world. Lilly is widely recognized for leadership in biotechnology, chemistry, and genetic medicine, advancing breakthrough therapies across diabetes, obesity, Alzheimer’s disease, immunology, and oncology, alongside a deep commitment to partnering with innovators and entrepreneurs.
At this session, Kristina Kitko, Director of Venture Science, will share insights into Lilly’s Corporate Business Development strategy and early-stage innovation across five core therapeutic areas. She manages Lilly’s external venture investments of over $2B globally and leads due diligence and evaluation efforts.
This program will include a presentation, audience Q&A, and networking, offering Washington state life science companies and researchers a valuable opportunity to gain direct insight into how to align with Lilly’s BD and venture priorities.
Whether you joined us previously or are attending for the first time, this session will provide important strategic perspective on partnering with Lilly!